Abstract
Background
The cell division cycle 7 (CDC7) is a serine–threonine kinase, which is required for DNA replication and is high expressed in diffuse large B cell lymphoma (DLBCL).
Methods
In this study, we targeted CDC7 in human DLBCL-ABC subtype cells (ly3) and examined the subsequent alterations in cellular apoptosis. The expression of CDC7 was silenced with small interfering RNA (siRNA)-expressing plasmid. CDC7 gene silencing cells were then incubated with or without rituximab for 24 h. Following treatment, Annexin V/propidium iodide staining followed by flow cytometry was used to examine cellular apoptosis. Furthermore, the expression of caspase 3, Bax, and Bcl-2 protein was analyzed by Western blotting. The expression of Bax and Bcl-2 mRNA was analyzed by quantitative real-time PCR.
Results
Compared to non-treated or control siRNA-transfected cells, significantly higher levels of apoptosis were detected in siCDC7-transfected cells and rituximab-treated cells (P < 0.05), which was further enhanced in CDC7-targeted cells with rituximab treatment (P < 0.05). The pro-apoptotic effects were accompanied with up-regulation of caspase 3 and Bax, meanwhile down-regulation of Bcl-2.
Conclusion
Combined treatments using rituximab and CDC7 gene silencing significantly increases apoptosis in ly3 cells and plays synergistic effect. CDC7 is a novel therapeutic target in DLBCL patients. CDC7 inhibitors combined with rituximab will be the new therapy for the ABC-DLBCL patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alas S, Bonavida B (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137–5144
Chu PG, Loera S, Huang Q, Weiss LM (2006) Lineage determination of CD20- B-cell neoplasms: an immunohistochemical study. Am J Clin Pathol 126:534–544
Cossman J, Tsujimoto Y, Jaffe E, Croce CM (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440–1443
Cragg MS, French RR, Glennie MJ (1999) Signaling antibodies in cancer therapy. Curr Opin Immunol 11:541–547
Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205–219
Deans JP, Schieven GL, Shu GL et al (1993) Association of tyrosine and serine kinases with B cell surface antigen CD20. J Immunol 151:4494–4504
Farnebo M, Bykov VJ, Wiman KG (2010) The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 396:85–89
Fisher RI, Shah P (2003) Current trends in large cell lymphoma. Leukemia 17(10):948–1960
Goping IS, Gross A, Lavoie JN et al (1998) Regulated targeting of BAX to mitochondria. J Cell Biol 143:207–215
Hernandez-Ilizaliturri FJ, Jupudy V, Oflazoglu E et al (2003) Neutrophils contribute to the biological anti-tumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency (SCID) mouse model. Clin Cancer Res 9:5866–5873
Im JS, Lee JK (2008) ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. J Biol Chem 283:25171–25177
Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Tumors of haematopoietic and lymphoid tissue. IARC Press, Lyon
Jazirehi AR, Vega MI, Chatterjee D, Goodglick L, Bonavida B (2004) Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin’s lymphoma B cells by Rituximab. Cancer Res 64:7117–7126
Krawczyk J, Egan C, Mulvihill M et al (2009) Increased activity of the S phase kinase Cdc7 is associated with poor outcome in diffuse large B cell lymphoma (DLBCL) [abstract]. Blood (ASH Annual Meeting Abstracts) 114:Abstract nr 1914
Leist M, Jaattela M (2001) Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2:589–598
Montagnoli A, Moll J, Colotta F (2010) Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res 16(18):4503–4508. Epub 2010 Jul 20. Review
Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 346(25):1937–1947
Shan D, Ledbetter JA, Press OW (1998) Apoptosis of malignant human B cell by ligation of CD20 with monoclonal antibodies. Blood 91:1644–1652
Wei MC, Zong WX, Cheng EH et al (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292:727–730
Yun H, Hua-qing W, Yi B (2012) High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma. Med Oncol [Epub ahead of print]
Acknowledgments
We have financial relationship with TianJin medical university that sponsored the research.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hou, Y., Wang, Hq. & Ba, Y. Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells. J Cancer Res Clin Oncol 138, 2027–2034 (2012). https://doi.org/10.1007/s00432-012-1283-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-012-1283-2